Denali Therapeutics initiated with an Outperform at Cowen

Cowen analyst Brendan Smith initiated coverage of Denali Therapeutics with an Outperform rating and no price target. The analyst has high conviction in the company’s transport vehicle platform given its "validated mechanism of action." The first approval in Hunter syndrome in 2026 should support expansion into multiple lucrative markets, Smith tells investors in a research note.